首页> 外文期刊>Target: World drug delivery news >Roche licenses Halozyme's Enhanze technology for dollar130m
【24h】

Roche licenses Halozyme's Enhanze technology for dollar130m

机译:罗氏以1.3亿美元的价格许可Halozyme的Enhanze技术

获取原文
获取原文并翻译 | 示例
           

摘要

Halozyme is to use its proprietary Enhanze technology to formulate Roche's biological therapeutic compounds after a licensing deal was stuck between the two companies. Enhanze is Halozyme's proprietary drug delivery technology based on its recombinant human hyaluronidase (rHuPH20), an analogue of a human enzyme that temporarily clears space within tissues such as skin. This clearing activity should allow rHuPH20 to improve drug delivery by enhancing the entry of therapeutic molecules through the subcutaneous space.
机译:在两家公司之间达成许可协议后,Halozyme将使用其专有的Enhanze技术来配制罗氏的生物治疗化合物。 Enhanze是Halozyme的专有药物递送技术,基于其重组人透明质酸酶(rHuPH20),后者是一种人类酶的类似物,可暂时清除皮肤等组织内的空间。这种清除活性应允许rHuPH20通过增强治疗性分子通过皮下空间的进入来改善药物递送。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号